Development
Taysha Gene Therapies, Inc.
TSHA
$2.71
-$0.085-3.05%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.35% | -32.13% | -23.82% | -11.29% | 17.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.87% | -49.68% | -47.65% | -25.96% | 11.48% |
| Operating Income | 53.94% | 54.91% | 51.43% | 27.41% | -11.48% |
| Income Before Tax | -33.29% | 33.07% | 30.52% | 4.51% | -13.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.29% | 33.07% | 30.52% | 4.51% | -13.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.29% | 33.07% | 30.52% | 4.51% | -13.24% |
| EBIT | 53.94% | 54.91% | 51.43% | 27.41% | -11.48% |
| EBITDA | 54.51% | 55.41% | 51.90% | 27.88% | -10.99% |
| EPS Basic | 37.61% | 52.49% | 45.58% | 17.79% | -8.94% |
| Normalized Basic EPS | 53.95% | 66.36% | 58.79% | 32.29% | -8.94% |
| EPS Diluted | 37.61% | 52.49% | 45.58% | 17.79% | -8.94% |
| Normalized Diluted EPS | 53.95% | 66.36% | 58.79% | 32.29% | -8.94% |
| Average Basic Shares Outstanding | 96.73% | 45.58% | 32.26% | 16.64% | 5.18% |
| Average Diluted Shares Outstanding | 96.73% | 45.58% | 32.26% | 16.64% | 5.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |